Kyowa Kirin Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Kyowa Kirin's estimated annual revenue is currently $168.8M per year.(i)
  • Kyowa Kirin's estimated revenue per employee is $201,000

Employee Data

  • Kyowa Kirin has 840 Employees.(i)
  • Kyowa Kirin grew their employee count by 3% last year.

Kyowa Kirin's People

NameTitleEmail/Phone
1
Chief Staff to the PresidentReveal Email/Phone
2
VP, Head Global Audit and R&D QualityReveal Email/Phone
3
Executive Assistant, Project OfficerReveal Email/Phone
4
VP, Head DigitalReveal Email/Phone
5
SVP General Counsel & Chief Compliance OfficerReveal Email/Phone
6
QA Associate Director, RP & BtM VPReveal Email/Phone
7
VP, ManufacturingReveal Email/Phone
8
Head Legal (Interim)Reveal Email/Phone
9
Head Warehousing and DistributionReveal Email/Phone
10
Head Tax, EMEA RegionReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.6M3332%N/AN/A
#2
$38M1896%N/AN/A
#3
$6.6M3322%N/AN/A
#4
$4180M152421%$550MN/A
#5
$17.5M8750%N/AN/A
#6
$6.7M125-37%$199.6MN/A
#7
$10.9M5415%N/AN/A
#8
$15.3M7633%N/AN/A
#9
$128.6M64016%N/AN/A
#10
$18.7M9321%N/AN/A
Add Company

What Is Kyowa Kirin?

As an agent for Kyowa Hakko Kirin (KHK), KKC is continuously searching for novel technologies and pharmaceutical products which represent licensing and/or partnering opportunities attractive to KHK's business platforms. KKC is interested in products and technologies that have been developed in both academic and industrial sectors. For potential in-licensing to KHK, KKC is looking for product candidates at any stage of development in the following core disease areas: Oncology, renal diseases, immune disorders and allergy. KKC also seeks partners who have novel technologies that can facilitate KHK's R&D efforts in the following fields

keywords:N/A

N/A

Total Funding

840

Number of Employees

$168.8M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Kyowa Kirin News

2022-04-20 - Mycosis Fungoides Treatment Market Size, Scope And ...

Kyowa Kirin Co. Ltd., Pfizer Inc., Astellas Pharma, Bayer AG, Elorac Dover Medical and Scientific Equipment, Ltd.

2022-04-06 - Ardelyx and Kyowa Kirin Amend License Agreement for ...

Kyowa Kirin is finalizing its Phase 3 clinical program for tenapanor for hyperphosphatemia and has disclosed its current expectation to file for...

2022-04-06 - Ardelyx amends license deal with Kyowa Kirin for tenapanor

Ardelyx and its Japanese collaboration partner Kyowa Kirin have amended their license agreement for tenapanor. contract-g78195e06a_1280.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$197M885-1%$482.8M
#2
$126.8M88810%N/A
#3
$179.7M89428%N/A
#4
$227.8M9043%N/A
#5
$165.6M91023%N/A